Artificial intelligence is described as a highly data-driven technology. Furthermore, AI technology is gradually making it’s way into the public through mobile healthcare applications. In addition, machine learning and predictive analytics research are being conducted to tailor treatment to an individual’s unique health history. Deep learning is ideally suited for drug development due to its unparalleled capacity to extract significant features from unprocessed raw data, regardless of the size of the data set. The market is segmented into drug discovery, biotechnology, clinical trials, medical diagnosis, precision and personalized medicine, and patient monitoring. North America is the most significant shareholder in the global artificial intelligence AI in life sciences market and is estimated to grow at a CAGR of 26.6% during the forecast period. Ltd.
NOTES: Artificial intelligence is described as a highly data-driven technology. In the life sciences industry, it is often deployed in the R&D capacities to give valuable insights from loosely connected data. The fastest-growing region is Europe, with Germany representing the biggest regional market for AI in the life sciences. The global artificial intelligence in life sciences market size was valued at USD 1,622 million in 2021.
